Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Fujifilm Launches US$3.2 Billion Biologics Plant in North Carolina
Fujifilm has opened a large-scale biologics manufacturing facility in Holly Springs, North Carolina, marking a major expansion of its CDMO operations in the US. Operated by subsidiary Fujifilm Biotechnologies, the plant will house a total of 16 20,000-liter mammalian cell…
To read the full story
Related Article
- Fujifilm Picked for FDA Pilot to Accelerate US CDMO Expansion
July 9, 2026
- Fujifilm CDMO Strikes US$3 Billion Manufacturing Deal with Regeneron
April 23, 2025
- Fujifilm to Invest 180 Billion Yen to Bolster Biologic CDMO Biz in North America
April 15, 2024
- Fujifilm to Build Cell Culture Media Manufacturing Center in US
November 25, 2022
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…